Positive Phase III trials of AstraZeneca's PT027, a fixed-dose combo for asthma patients

9 September 2021

Positive high-level results have been released from the MANDALA and DENALI Phase III trials of PT027 (albuterol/budesonide), at both 180/160mcg and 180/80mcg doses, showing the meeting of all primary endpoints and demonstrating statistically-significant benefits in patients with asthma versus individual components albuterol, also known as salbutamol (180mcg) and budesonide (160mg).

PT027 is a potential first-in-class inhaled, fixed-dose combination of albuterol, a short-acting beta2-agonist (SABA), and budesonide, an inhaled corticosteroid (ICS), being developed by Anglo-Swedish pharm major AstraZeneca (LSE: AZN) and Avillion, a drug development company focused on the co-development and financing of pharmaceutical candidates, from proof-of-concept through to regulatory approval.

This continues Avillion’s successful record in clinical co-development partnerships for the global pharmaceutical and biotech industry, including with Pfizer’s (NYSE: PFE) on Bosulif (bosutinib) and with German drugmaker Merck KGaA (MRK: DE) in plaque psoriasis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK